BNIP3 Antibody (6A5F7) - BSA Free

Flow Cytometry: BNIP3 Antibody (6A5F7) - BSA Free [NBP2-61715]

Flow Cytometry: BNIP3 Antibody (6A5F7) [NBP2-61715] - Analysis of Hela cells using BNIP3 mouse mAb (green) and negative control (red).

Western Blot: BNIP3 Antibody (6A5F7)BSA Free [NBP2-61715]

Western Blot: BNIP3 Antibody (6A5F7) [NBP2-61715] - Analysis using BNIP3 mAb against HEK293 (1) and BNIP3 (AA: 50-155)-hIgGFc transfected HEK293 (2) cell lysate.

Immunohistochemistry-Paraffin: BNIP3 Antibody (6A5F7) - BSA Free [NBP2-61715]

Immunohistochemistry-Paraffin: BNIP3 Antibody (6A5F7) [NBP2-61715] - Analysis of breast cancer tissues using BNIP3 mouse mAb with DAB staining.

ELISA: BNIP3 Antibody (6A5F7) - BSA Free [NBP2-61715]

ELISA: BNIP3 Antibody (6A5F7) [NBP2-61715] - Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)

Western Blot: BNIP3 Antibody (6A5F7) - BSA Free [NBP2-61715] -

Hypoxia and Cocl2 exposure modifies the H9c2 cells Cav1.2 (CACNA1C) expression both at mRNA and protein level. (A) Cav1.2, mRNA expression levels, (B) Cav1.2 Protein expression levels and representative western blots. Compared to Controls Hypoxia increased the Cav1.2 expression at mRNA (****p < 0.0001) and Protein level (***p < 0.001). In addition, Cav1.2 mRNA levels are increased in Cocl2 + ECM (**p < 0.002) exposed cells. Compared to Hypoxia (1%O2), cells exposed to 1%O2 + A2P (####p < 0.0001), 1%O2 + ECM (####p < 0.0001) and in Beclin-1 inhibition cells grown under Hypoxia expressed significant decrease in Cav1.2 mRNA (####p < 0.0001) and Protein (###p < 0.001) expression levels. Data represents, n = 3 (mRNA) and n = 5 (Protein) independent samples/group. Bars are mean +/- S.D. Symbols *, +, #, and ≠ denotes significant, “ns" represents not significant by two-way ANOVA- multiple comparisons test. P-values are nsp > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 compared to Control; +p < 0.05, ++p < 0.01, + + +p < 0.001 and + + + +p < 0.0001 compared to Cocl2; #p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.0001 compared to Hypoxia; ≠p < 0.05, ≠≠p < 0.01, ≠≠≠p < 0.001, and ≠≠≠≠p < 0.0001 compared to si-becn1 (21%O2) Vs, si-becn1 (1%O2). In western blots “→" represents a specific signal. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35928940), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: BNIP3 Antibody (6A5F7) - BSA Free [NBP2-61715] -

Hypoxia and Cocl2 exposure not significantly altered the H9c2 cells Cav1.1 (CACNA1S) mRNA and protein expression levels. (A) Cav1.1 mRNA expression levels, (B) Cav1.1 Protein expression levels, and representative western blots. Cav1.1 mRNA levels was increased in h9c2 cells exposed to Cocl2 + ECM (****p < 0.0001), and not changed significantly in Control vs. Cocl2, Cocl2 + A2P, 1%O2 + A2P, 1%O2 + ECM, and in Beclin-1 inhibition cells grown under normoxia and hypoxia conditions. Compared to Hypoxia (1%O2), cells exposed to 1%O2 + A2P (#p < 0.010), 1% O2 + ECM, (####p < 0.0001), and in Beclin-1 inhibition (###p < 0.0005) cells grown under Hypoxia expressed significant decrease in Cav1.1 mRNA levels. However, Cav 1.1 protein expression levels only decreased in (*p < 0.047) Beclin-1 inhibition cells under hypoxia and not significantly changed in all other experimental groups. Data represents, n = 3 (mRNA) and n = 5 (Protein) independent samples/group. Bars are mean +/- S.D. Symbols *, +, #, and ≠ denotes significant, “ns" represents not significant by two-way ANOVA- multiple comparisons test. P-values are nsp > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 compared to Control; +p < 0.05, ++p < 0.01, + + +p < 0.001, and + + + +p < 0.0001 compared to Cocl2; #p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.0001 compared to Hypoxia; ≠p < 0.05, ≠≠p < 0.01, ≠≠≠p < 0.001, and ≠≠≠≠p < 0.0001 compared to si-becn1 (21%O2) Vs, si-becn1 (1%O2). In western blots “→" represents a specific signal. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35928940), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: BNIP3 Antibody (6A5F7) - BSA Free [NBP2-61715] -

Hypoxia, Cocl2 exposure decrease the Autophagy protein-Becn1 (Beclin-1) expression at mRNA and Protein level. (A)Becn1 mRNA expression levels (B),Becn1 protein expression levels and representative western blots showing Becn1 protein levels in H9c2 cells treated with ECM, A2P, siRNA-Beclin1 and grown under CoCl2, Hypoxia (1%O2), and Normoxia conditions (21%O2). Becn1 mRNA levels was decreased in h9c2 cells exposed to Cocl2 (****p < 0.0001), Cocl2 + ATP (**p < 0.004) and Cocl2 + ECM (****p < 0.0001). Becn1 mRNA levels decreased in Hypoxia cells (1%O2) (*p < 0.019) and in Hypoxia (1%O2) + ECM, ***p < 0.0001. Beclin-1 inhibition decreased the becn1 mRNA levels in normoxia (21%O2) ****p < 0.0001 and in hypoxia (1%O2) (****p < 0.0001) exposed cells. Becn1 protein expression levels also decreased in Cocl2 (****p < 0.0001), Cocl2 + A2P (****p < 0.0001), Cocl2 + ECM (****p < 0.0001), and in Hypoxia (1%O2) *p < 0.026, and in 1%O2 + ECM (****p < 0.0001). Beclin-1 inhibition confirms the decreased Becn1 protein under normoxia (21%O2) exposure (****p < 0.0001) and in Hypoxia (***p < 0.0003). Data represents, n = 3 (mRNA) and n = 6 (Protein) independent samples/group; Bars are mean +/- S.D. Symbols *, +, # and ≠ denotes significant, “ns" represents not significant by two-way ANOVA- multiple comparisons test. P-values are nsp > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 compared to Control; +p < 0.05, ++p < 0.01, + + +p < 0.001, and + + + +p < 0.0001 compared to Cocl2; #p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.0001 compared to Hypoxia; ≠p < 0.05, ≠≠p < 0.01, ≠≠≠p < 0.001, and ≠≠≠≠p < 0.0001 compared to si-becn1 (21%O2) Vs, si-becn1 (1%O2). In western blots “→" represents a specific signal. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35928940), licensed under a CC-BY license. Not internally tested by Novus Biologicals.